Quick Comparison

SulbutiamineTianeptine
Half-Life5 hours2.5-3 hours (tianeptine), 7-8 hours (active metabolite MC5)
Typical DosageStandard: 200-600 mg daily in 1-2 doses. Take with food (fat-soluble). Tolerance can develop with daily use — best cycled or used intermittently.Prescription dose: 12.5 mg three times daily (Stablon). Extended-release: 25 mg once daily (Tianeurax). Do not exceed prescribed doses — abuse potential at higher doses due to opioid activity.
AdministrationOral (capsules, tablets). Fat-soluble — take with food.Oral (tablets). Immediate-release (12.5 mg TID) or extended-release (25 mg QD).
Research Papers10 papers10 papers
Categories

Mechanism of Action

Sulbutiamine

Sulbutiamine consists of two thiamine (vitamin B1) molecules connected by a disulfide bridge, conferring lipophilicity and efficient blood-brain barrier penetration via passive diffusion. In the brain, it is hydrolyzed to thiamine and increases thiamine diphosphate (TDP) levels—the cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase, enzymes critical for glucose metabolism and the Krebs cycle. Sulbutiamine upregulates D1 dopamine receptors in the prefrontal cortex, possibly through reduced receptor internalization or increased expression. It modulates glutamatergic transmission (affecting NMDA/AMPA receptor function) and enhances cholinergic transmission. The anti-fatigue and memory-enhancing effects likely stem from improved neuronal glucose oxidation, increased ATP production, and enhanced dopaminergic and cholinergic tone in cognitive circuits.

Tianeptine

Tianeptine is a full agonist at mu-opioid (MOR) and delta-opioid (DOR) receptors, mediating both its antidepressant/anxiolytic effects and abuse potential at high doses. Paradoxically, it enhances serotonin reuptake via SERT—opposite to SSRIs—yet still produces antidepressant effects, possibly through opioid-mediated mood regulation. Tianeptine modulates glutamatergic signaling by reversing stress-induced downregulation of AMPA receptor subunits (GluA1/GluA2) and restoring synaptic plasticity. In the hippocampus and amygdala, it prevents stress-induced dendritic atrophy, spine loss, and CA3 pyramidal cell damage—likely through opioid receptor activation and downstream HPA axis effects. It increases BDNF levels and promotes neurogenesis. The combination of opioid agonism, glutamate normalization, and neuroplasticity enhancement underlies its unique profile.

Risks & Safety

Sulbutiamine

Common

Headache, insomnia, irritability, nausea. Tolerance develops with daily use.

Serious

No serious adverse effects documented.

Rare

Skin rash, mood instability, agitation.

Tianeptine

Common

Nausea, constipation, abdominal pain, headache, dizziness, dry mouth.

Serious

Opioid-like effects at high doses (euphoria, dependence, respiratory depression). Withdrawal syndrome with abrupt cessation after chronic high-dose use. Abuse and overdose deaths reported.

Rare

Hepatotoxicity, skin reactions.

Full Profiles